Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 165Sarcoma 37Gastrointestinal 12Thoracic 9Dermatologic 9Lymphoid 7Endocrine 7Genitourinary 5Tumor-Agnostic 4NET 3Breast 3Gynecologic 2Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Neuroendocrine Tumors 3Small Cell Lung Carcinoma 1Lung Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 28Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4Capecitabine 4olaparib 3copper dotatate CU-64 3atezolizumab 3Temozolomide 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Temozolomide × NET × 1 year × Clear all
NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
70 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
55 enrolled
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡